Mumbai: Biocon Ltd, Asia’s largest biotech company, on Friday said it had entered into an exclusive deal with US-based CytoSorbents Corp. to sell its CytoSorb blood-purification device in India.
Biocon and CytoSorbents will initially focus on using the device in the treatment of sepsis—the end result of an excessive immune response to infection.
“We believe our partnership with CytoSorbents will enable us to address the huge unmet need of sepsis management in India and emerging markets,” Kiran Mazumdar-Shaw, chairperson and managing director, Biocon, said in a statement.
Severe sepsis and septic shock are leading causes of deaths in non-coronary intensive care units (ICUs) and the 11th leading cause of death overall, according to an article published (2010) in Indian Journal of Critical Care Medicines. Over one-third of the patients who develop sepsis die globally.
In India, more than one million estimated new cases of severe sepsis are treated each year, accounting for one of every four patients in ICUs, an article said.
According to a recent study, Indian Intensive Care Case Mix and Practice Patterns, involving 124 ICUs across 17 states in India, mortality was found to be as high as 46% in patients with septic shock and 42.2% overall in septic patients, compared with 17.8% mortality for ICU patients who did not develop sepsis.
Shares of Biocon were down 1.51% at Rs.333.10 at 12:45pm on BSE, while the Sensex at 19,777.82 points was down 0.02%.